胆管癌临床试验招募信息（全球在招）

这里汇总了全球正在招募患者的 胆管癌（国际通用名 cholangiocarcinoma）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖胆道癌、胆囊癌等说法。

正在招募的胆管癌新药试验

• Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

  II 期招募中中国NCT06280508

• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  I 期 / II 期招募中美国日本NCT07488676

• Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

  IV 期招募中美国NCT07486713

• Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer

  II 期招募中SwitzerlandNCT06274879

• Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

  I 期 / II 期招募中美国NCT03942328

• Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma

  II 期招募中中国NCT07105852

• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  不适用招募中美国NCT04907643

• Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

  不适用招募中South KoreaNCT06168292

• The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

  不适用招募中美国NCT07224464

• A IIT Study of 177Lu-DOTA-SNA040

  早期 I 期招募中中国NCT07595237

• Liver Embolization Approaches for Tumor Management

  不适用招募中意大利NCT05714124

• Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients

  I 期 / II 期招募中中国台湾NCT06730009